Table 2.
Clinical risk score, metabolic characteristics and metabolic clinical risk score in DHGP and non‐DHGP groups
| DHGP (n = 22) | Non‐DHGP (n = 86) | P value | |
|---|---|---|---|
| KRAS mutation | 9 (47.4%) | 33 (42.9%) | 0.799 |
| Clinical risk score, n (%) | 0.585 | ||
| 0 | 1 (4.5%) | 3 (3.5%) | |
| 1 | 2 (9.1%) | 13 (15.1%) | |
| 2 | 8 (36.4%) | 30 (34.9%) | |
| 3 | 7 (31.8%) | 31 (36%) | |
| 4 | 4 (18.2%) | 6 (7%) | |
| 5 | 0 | 3 (3.5%) | |
| High risk clinical risk score, n (%) | 11 (50%) | 40 (46.5%) | 0.814 |
| SUVmax/SUVmean(liver) | 3.16 (1.74) | 4.26 (2.5) | 0.009 |
| SUVmax/SUVmean(liver) > 4.3 | 3 (13.6%) | 43 (50%) | 0.003 |
| Metabolic clinical risk score | 0.94 | ||
| 0 | 1 (4.5%) | 3 (3.5%) | |
| 1 | 2 (9.1%) | 8 (9.3%) | |
| 2 | 7 (31.8%) | 19 (22.1%) | |
| 3 | 7 (31.8%) | 33 (38.4%) | |
| 4 | 4 (18.2%) | 15 (17.4%) | |
| 5 | 1 (4.5%) | 5 (5.8%) | |
| 6 | 0 | 3 (3.5%) | |
| High risk metabolic clinical risk score | 5 (22.7%) | 23 (26.7%) | 0.791 |
| Neoadjuvant chemotherapy | 19 (86.4%) | 66 (76.7%) | 0.396 |
| Immunotherapy | 0.835 | ||
| Bevacizumab | 2 (9.1%) | 8 (9.3%) | |
| Cetuximab | 3 (13.6%) | 8 (9.3%) |